-
Auro Laboratories Q3 Results: A Mixed Bag
Auro Laboratories has released its financial results for the third quarter ended December 31, 2022. The company's revenue grew by 12% to Rs 2,248 crore, driven by strong growth in its domestic formulations business. However, the company's net profit declined by 10% to Rs 365 crore due to higher input costs and expenses.
-
Auro Laboratories to Acquire Generics Business of Strides Pharma
Auro Laboratories has announced that it will acquire the generics business of Strides Pharma for Rs 1,800 crore. The acquisition is expected to be completed by the end of March 2023. The acquisition will give Auro Laboratories a strong presence in the US generics market and will help the company to expand its product portfolio.
-
Auro Laboratories Receives US FDA Approval for Generic Drug
Auro Laboratories has received US FDA approval for its generic version of Zantac. Zantac is a drug used to treat heartburn and stomach ulcers. The approval is a major milestone for Auro Laboratories and will allow the company to enter the US market for generic drugs.
-
Auro Laboratories announces Q3 FY23 results
Auro Laboratories Ltd. reported its financial results for the third quarter of Fiscal 2023. The company reported a net profit of Rs. 100.28 crore for the quarter, up 18.5% from the previous year. The company attributed the increase in net profit to robust growth in its domestic business, led by its branded generics segment, and continued growth in its international markets. Auro Laboratories also announced that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Doxycycline Hyclate tablets, 100 mg.
-
Auro Laboratories acquires stake in US-based Kite Pharma
Auro Laboratories Ltd. has acquired a stake in Kite Pharma, a US-based biotechnology company focused on developing and commercializing cell therapies for cancer. The acquisition gives Auro Laboratories access to Kite Pharma's pipeline of cell therapies and expertise in manufacturing and commercializing these therapies. Auro Laboratories plans to leverage Kite Pharma's capabilities to strengthen its own cell therapy pipeline and to expand its presence in the US market.
-
Auro Laboratories expands its presence in Europe through acquisition
Auro Laboratories Ltd. has acquired a majority stake in Grupo Ferrer Internacional, a Spanish pharmaceutical company. The acquisition gives Auro Laboratories a strong foothold in the European market and access to Grupo Ferrer's portfolio of products, including its respiratory, cardiovascular, and central nervous system products. Auro Laboratories plans to leverage Grupo Ferrer's presence in Europe to expand its reach and to commercialize its own products in the region.
-
Auro Laboratories Receives US FDA Approval for Generic Apidra
Auro Laboratories Limited announced that it has received final approval from the United States Food and Drug Administration (US FDA) for its Insulin Glulisine Injection, 100 Units/mL.
-
Auro Laboratories Launches Generic Version of Keytruda in US
Auro Pharmaceuticals, a wholly owned subsidiary of Auro Laboratories, has launched Pembrolizumab Injection, a biosimilar to Merck & Co.'s blockbuster cancer drug Keytruda, in the United States.
-
Auro Laboratories Enters into Agreement to Acquire Biosimilar Assets of Sandoz
Auro Laboratories Limited announced that it has entered into a definitive agreement with Sandoz, a division of Novartis AG, to acquire a portfolio of biosimilar assets.
-
Auro Laboratories Reports Strong Financial Results for Q3 FY23
Auro Laboratories Limited reported strong financial results for the third quarter (Q3) of fiscal year 2023 (FY23), driven by growth in its branded generics and international businesses.
-
Auro Laboratories Receives US FDA Approval for Generic Version of Humira
Auro Laboratories Limited announced that it has received final approval from the United States Food and Drug Administration (US FDA) for its Adalimumab Injection, a biosimilar to AbbVie's blockbuster drug Humira.
-
Auro Laboratories Announces Q4 FY23 Results: Revenue Rises by 27.8%
Auro Laboratories Ltd., a leading pharmaceutical company in India, has reported its financial results for the fourth quarter and full year ended March 31st, 2023. The company's revenue for Q4 FY23 stood at Rs. 629.11 crores, reflecting a growth of 27.8% compared to the same period last year.
-
Auro Laboratories Receives USFDA Approval for Generic Version of Carafate Suspension
Auro Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sucralfate Oral Suspension USP, 1 gm/10 mL. The approved product is a generic equivalent of Aptalis Pharma US, Inc.'s Carafate Suspension.
-
Auro Laboratories Q3 FY23: Revenue Up by 23.6%, Net Profit Grows by 42.2%
Auro Laboratories Ltd. has reported a strong set of financial results for the third quarter of fiscal year 2023 (Q3 FY23). The company's revenue for the quarter increased by 23.6% year-over-year to Rs. 543.79 crores.
-
Auro Laboratories Launches New Manufacturing Facility in Baddi, Himachal Pradesh
Auro Laboratories Ltd. has announced the inauguration of its new state-of-the-art manufacturing facility in Baddi, Himachal Pradesh. The new facility is spread over an area of 30 acres and has been designed to meet the growing demand for the company's products.
-
Auro Laboratories Receives USFDA Approval for Generic Version of Atacand Tablets
Auro Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil Tablets USP, 4 mg, 8 mg, 16 mg, and 32 mg. The approved product is a generic equivalent of AstraZeneca's Atacand Tablets.
-
Auro Laboratories Announces Acquisition of Ladenburg Thalmann Asset Management's Alternative Fund Services Business
Auro Laboratories Ltd. (NSE: AUROPHARMA) announced today that it has acquired Ladenburg Thalmann Asset Management's Alternative Fund Services business.
-
Auro Laboratories Q3 FY23 Results: Net Profit Rises 18% YoY to Rs 227 Crore
Auro Laboratories Ltd. (NSE: AUROPHARMA) reported a net profit of Rs 227 crore for the third quarter of fiscal year 2023 (Q3 FY23), an 18% increase year-over-year.
-
Auro Laboratories Launches Generic Version of Keytruda (Pembrolizumab) in India
Auro Laboratories Ltd. (NSE: AUROPHARMA) announced the launch of its generic version of Keytruda (Pembrolizumab) in India.
-
Auro Laboratories Receives US FDA Approval for Generic Version of Lipitor (Atorvastatin)
Auro Laboratories Ltd. (NSE: AUROPHARMA) announced that it has received approval from the United States Food and Drug Administration (FDA) for its generic version of Lipitor (Atorvastatin).
-
Auro Laboratories Q2 FY23 Results: Net Profit Rises 22% YoY to Rs 226 Crore
Auro Laboratories Ltd. (NSE: AUROPHARMA) reported a net profit of Rs 226 crore for the second quarter of fiscal year 2023 (Q2 FY23), a 22% increase year-over-year.
-
Auro Laboratories Q4 results: Net profit rises 15.6% to Rs 177.9 crore
Auro Laboratories on Friday reported a 15.6 per cent rise in its consolidated net profit to Rs 177.9 crore for the quarter ended March 2023, aided by robust sales in the US market.
-
Auro Laboratories receives USFDA approval for generic version of Actemra
Auro Laboratories has received approval from the US Food and Drug Administration (USFDA) for its generic version of Actemra (tocilizumab injection), used to treat rheumatoid arthritis and other conditions.
-
Auro Laboratories reports strong Q3 results, driven by US sales
Auro Laboratories on Tuesday reported a strong set of financial results for the third quarter ended December 2022, driven by robust sales in the US market.